Multiple reverse splits in rapid succession signal severe distress and potential Nasdaq delisting risk. Monitor the stock's post-split price action — if it fails to sustain above $1.00, delisting becomes highly probable. The prior 1-for-10 split in September 2025 did not resolve the bid-price deficiency, suggesting fundamental issues remain.
Price Chart
Executive Summary
Lunai Bioworks announced a 1-for-8 reverse stock split effective May 22, 2026, aimed at regaining compliance with Nasdaq's $1.00 minimum bid price rule. This is the company's second reverse split in eight months, following a 1-for-10 split on September 30, 2025. The split reduces outstanding shares from ~36.3M to ~4.5M but does not change the authorized share count or par value.
Key Facts
- 1-for-8 reverse stock split effective May 22, 2026
- Reduces outstanding shares from ~36,271,119 to ~4,533,890
- Second reverse split in 8 months (prior 1-for-10 on Sept 30, 2025)
- Intended to regain compliance with Nasdaq Listing Rule 5550(a)(2) ($1.00 minimum bid price)
- Stockholders approved split ratio range of 1-for-3 to 1-for-30 at May 8, 2026 special meeting
- Market cap of $9M indicates micro-cap distress
Financial Impact
No direct financial impact; share count reduced from ~36.3M to ~4.5M. No change to authorized shares or par value.
Risk Factors
- Nasdaq delisting if post-split price fails to sustain above $1.00
- Reduced liquidity and wider bid-ask spreads post-split
- Repeated reverse splits signal structural financial weakness
- Potential for further dilution if the company needs additional capital
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001731122-26-000759 |
| Document: e7662_ex99-1.htm | 0001731122-26-000759 |
| Document: 0001731122-26-000759-index-headers.html | 0001731122-26-000759 |
| Document: 0001731122-26-000759-index.html | 0001731122-26-000759 |
| Document: 0001731122-26-000759.txt | 0001731122-26-000759 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 22, 2026 3d ago | 8-K | $0.2946 $0.2750 | ▲ +6.65% | ▲ +7.36% | $0.2950 (−0.14%) |
Oct 15, 2026 10d ago | SC 13D/A | $0.6800 $0.4720 | ▲ +30.59% | ▲ +31.01% | $0.2950 (+56.62%) |
Oct 9, 2026 17d ago | 8-K | $1.23 $1.11 | ▲ +9.76% | ▲ +9.70% | $0.2950 (+76.02%) |
Sep 29, 2026 27d ago | NT 10-K | $1.47 $1.38 | ▲ +6.12% | ▲ +6.30% | $0.2950 (+79.93%) |
Jun 17, 2026 18w ago | 8-K | $3.78 $4.15 | ▲ +9.79% | ▲ +10.10% | $0.2950 (−92.20%) |
Jun 16, 2026 18w ago | 8-K | $4.00 $3.78 | ▼ −5.50% | ▼ −6.28% | $0.2950 (−92.63%) |
May 20, 2026 22w ago | 8-K | $1.80 $2.32 | ▼ −28.89% | ▼ −28.69% | $0.2950 (+83.61%) |
May 1, 2026 25w ago | 8-K | $2.60 $2.50 | ▼ −3.88% | ▼ −4.68% | $0.2950 (−88.64%) |
Apr 28, 2026 25w ago | DEFA14A | $2.66 $2.64 | ▼ −0.90% | ▼ −1.92% | $0.2950 (−88.93%) |
Mar 5, 2026 33w ago | 8-K | $1.86 $1.76 | ▲ +5.25% | ▲ +6.10% | $0.2950 (+84.12%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers